Primary human papillomavirus screening for cervical cancer in the United States—US Food and Drug Administration approval, clinical trials, and where we are today

Publisher： John Wiley & Sons Inc

E-ISSN： 1934-6638|122|10|720-729

ISSN： 1934-662x

Source： CANCER CYTOPATHOLOGY, Vol.122, Iss.10, 2014-10, pp. : 720-729

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 761-767

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3489-3495

John Wiley & Sons Inc

Access to resources Recommend Favorite

Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 2, 2015-07 ,pp. : 420-427

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interim Guidelines Describe Using High‐Risk Human Papillomavirus Testing as Alternative for Primary Cervical Cancer Screening

By  

JOURNAL OF MIDWIFERY & WOMEN'S HEALTH, Vol. 60, Iss. 3, 2015-05 ,pp. : 330-331

John Wiley & Sons Inc

Access to resources Recommend Favorite

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

By  

CANCER, Vol. 120, Iss. 19, 2014-10 ,pp. : 3025-3032

John Wiley & Sons Inc

Access to resources Recommend Favorite